Journal of the neurological sciences · 2026
Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS.
СтатьяНаблюдательное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
France-Ratcliffe Madeleine, Harrison Stephanie L, Verma Leona A, Abdul-Rahim Azmil H, McCallum Linsay, McDowell Garry, Young Carolyn A, Buckley Benjamin J R
Аннотация
BACKGROUND: Comorbidities may exacerbate disease burden in people with Multiple Sclerosis (pwMS), yet their influence on disease progression and patient-reported outcomes (PROs) remains poorly understood. Understanding how comorbidities relate to progression and PROs can inform personalised care.
OBJECTIVES: Identify comorbidity profiles in pwMS and assess their impact on MS type progression and PROs.
METHODS: This observational study analysed UK MS Register data from 2011 to 2025. Hierarchical clustering was based on cardiovascular and mental health comorbidities. Logistic and linear regression examined associations between clusters, comorbidities, progression and PROs.
RESULTS: Cluster analysis in 5944 pwMS identified 3 clusters: 1 (no comorbidities, n = 4278), 2 (100% cardiovascular, 5% mental health, n = 910), and 3 (98% mental health, 24% cardiovascular, n = 756). Amongst participants with relapsing-remitting MS at baseline (n = 4942), compared to cluster 1, cluster 2 showed no difference in odds (OR 1.15, 95%CI: 0.93-1.43) whilst cluster 3 greater odds (OR 1.90, 95%CI: 1.53-2.35) of progressing to secondary-progressive MS, after adjusting for age, gender, and time since diagnosis. Depression showed the strongest association with progression. Comorbidities were associated with worse PROs, with anxiety and depression linked to lower psychological and physical symptoms.
CONCLUSIONS: Mental health conditions clustered with cardiovascular multimorbidity consistently associated with poorer MS progression and prognosis, emphasising the need for integrated mental health management in pwMS.
OBJECTIVES: Identify comorbidity profiles in pwMS and assess their impact on MS type progression and PROs.
METHODS: This observational study analysed UK MS Register data from 2011 to 2025. Hierarchical clustering was based on cardiovascular and mental health comorbidities. Logistic and linear regression examined associations between clusters, comorbidities, progression and PROs.
RESULTS: Cluster analysis in 5944 pwMS identified 3 clusters: 1 (no comorbidities, n = 4278), 2 (100% cardiovascular, 5% mental health, n = 910), and 3 (98% mental health, 24% cardiovascular, n = 756). Amongst participants with relapsing-remitting MS at baseline (n = 4942), compared to cluster 1, cluster 2 showed no difference in odds (OR 1.15, 95%CI: 0.93-1.43) whilst cluster 3 greater odds (OR 1.90, 95%CI: 1.53-2.35) of progressing to secondary-progressive MS, after adjusting for age, gender, and time since diagnosis. Depression showed the strongest association with progression. Comorbidities were associated with worse PROs, with anxiety and depression linked to lower psychological and physical symptoms.
CONCLUSIONS: Mental health conditions clustered with cardiovascular multimorbidity consistently associated with poorer MS progression and prognosis, emphasising the need for integrated mental health management in pwMS.